JP2004533250A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533250A5
JP2004533250A5 JP2002592975A JP2002592975A JP2004533250A5 JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5 JP 2002592975 A JP2002592975 A JP 2002592975A JP 2002592975 A JP2002592975 A JP 2002592975A JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5
Authority
JP
Japan
Prior art keywords
cell
cells
domain
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002592975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533250A (ja
Filing date
Publication date
Priority claimed from GBGB0112687.9A external-priority patent/GB0112687D0/en
Application filed filed Critical
Publication of JP2004533250A publication Critical patent/JP2004533250A/ja
Publication of JP2004533250A5 publication Critical patent/JP2004533250A5/ja
Pending legal-status Critical Current

Links

JP2002592975A 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用 Pending JP2004533250A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
PCT/GB2002/002384 WO2002096467A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009202601A Division JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Publications (2)

Publication Number Publication Date
JP2004533250A JP2004533250A (ja) 2004-11-04
JP2004533250A5 true JP2004533250A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=9915236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002592975A Pending JP2004533250A (ja) 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Country Status (8)

Country Link
US (1) US20040208889A1 (cg-RX-API-DMAC10.html)
EP (1) EP1390400A2 (cg-RX-API-DMAC10.html)
JP (2) JP2004533250A (cg-RX-API-DMAC10.html)
CN (1) CN100439394C (cg-RX-API-DMAC10.html)
AU (1) AU2002256803B2 (cg-RX-API-DMAC10.html)
CA (1) CA2448963A1 (cg-RX-API-DMAC10.html)
GB (1) GB0112687D0 (cg-RX-API-DMAC10.html)
WO (1) WO2002096467A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
US20060068469A1 (en) * 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
WO2006023332A2 (en) * 2004-08-20 2006-03-02 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
US8092806B2 (en) * 2005-04-11 2012-01-10 Yeda Research And Development Co. Ltd. Chimeric proteins, their preparation and pharmaceutical compositions containing them
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2011117259A1 (en) * 2010-03-23 2011-09-29 Imba - Institut Für Molekulare Biotechnologie Gmbh Methods for identifying inhibitors of the type iii secretion system
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
KR101839496B1 (ko) 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
KR20180021703A (ko) * 2015-05-15 2018-03-05 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US20210054033A1 (en) 2018-01-25 2021-02-25 The Wistar Institute Of Anatomy And Biology Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
DE69511860T2 (de) * 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2001019393A1 (en) * 1999-09-13 2001-03-22 Cornell Research Foundation, Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iii secretion systems

Similar Documents

Publication Publication Date Title
Kosikowska et al. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)
KR102139844B1 (ko) 암 표적화 치료용 알부민-결합 아르기닌 데이미나제를 포함하는 약제학적 조성물
CN101675067B (zh) 肽组合物的修饰以提高稳定性和递送效率
CA2482598A1 (en) Peptide inhibitors of protein kinase c
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
CN101946001A (zh) 多肽-核酸结合物及其应用
Hilchie et al. Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03
JP2009286794A (ja) 分泌された細菌エフェクタータンパク質の薬学的使用
NZ606480A (en) Albumin binding peptide-mediated disease targeting
KR20210057072A (ko) 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법
Agyei et al. Peptides for biopharmaceutical applications
EP1523336B1 (en) Targeted agents for nerve regeneration
AU2002256803A1 (en) Pharmaceutical use for secreted bacterial effector proteins
BRPI1014631A2 (pt) peptídeos e seus usos.
WO2021046398A3 (en) Combination antiviral therapy for measles
JP2021525711A5 (cg-RX-API-DMAC10.html)
Suk Choi et al. Cell penetrating peptides for tumor targeting
JP2016509997A (ja) 骨粗鬆症を抑制するための治療
MX2025008278A (es) Conjugados anticuerpo-farmaco anti-cd70
Sarfaraz et al. Recent updates on peptide molecules in drug and vaccine development
KR102181505B1 (ko) 가려움증 억제
JP6530768B2 (ja) サイトカイン−キトサンバイオコンジュゲート及びその使用方法
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
WO2014020209A1 (es) Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal
JP2003513941A (ja) 溶菌毒素および毒素結合体の使用